Terms: = Ovarian cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Clinical Outcome
3 results:
1. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the ago Study Group.
Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
[TBL] [Abstract] [Full Text] [Related]
2. Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the ago Germany experience.
Hilpert F; Wimberger P; du Bois A; Pfisterer J; Harter P
Onkologie; 2012; 35(3):76-81. PubMed ID: 22414969
[TBL] [Abstract] [Full Text] [Related]
3. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract] [Full Text] [Related]
